Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Benign Prostatic Hyperplasia, LUTS, and Neurological Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADRA1A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Lentivirus Particle | ADRA1A Full-Length Premade Particles. HEK293 Expressed (Native Glycosylation). Sequence Verified. For functional cell-surface GPCR assays. | View ADRA1A Products |
| Gene Delivery | ADRA1A Promise-ORF Clone. Full-length coding sequence for custom stable cell line generation. | View ADRA1A Products |
| Benchmark Ab | Anti-ADRA1A Reference Antibody. Recombinant positive control for flow cytometry and receptor detection. | View ADRA1A Products |
| Validator | ADRA1A siRNA Set. For knockdown verification and target specificity confirmation. | View ADRA1A Products |
| Related Target A | ADRA1B. Subtype selectivity counter-screening; critical for minimizing cardiovascular off-target effects. | View ADRA1B Products |
| Related Target B | ADRA1D. Subfamily selectivity profiling; assesses vascular and lower urinary tract off-target liability. | View ADRA1D Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity | Full-length Lentivirus Particles for Stable Cell Lines. Preserves native 7-TM folding in mammalian membrane. |
| Subtype Selectivity (1A vs 1B/1D) | ADRA1A/1B/1D Ortholog Panel. All constructs Sequence Verified. HEK293 Expressed for native glycosylation patterns. |
| Calcium Flux Signaling | Compatible with Gα15/16 coupling cell lines. Endotoxin <1EU/μg prevents false positives. |
| Target Engagement Verification | Validated siRNA Set included for knockdown specificity confirmation. |
Live ADRA1A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for ADRA1A (Alpha-1A adrenergic receptor) remains dominated by small molecule antagonists for benign prostatic hyperplasia (BPH) and hypertension management. While first-generation non-selective alpha-blockers established the market, current R&D emphasizes subtype-selective small molecules (1A vs 1B/1D) to minimize cardiovascular side effects. Emerging trends include tissue-specific delivery formulations and exploration of allosteric modulators. The development landscape is now expanding toward novel indications including stress urinary incontinence, PTSD, and cognitive decline, driving the need for highly specific assay reagents that can distinguish subtle receptor conformations and downstream signaling pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonists | Astellas, Sanofi, AbbVie, Watson Labs | Benign Prostatic Hyperplasia (BPH), Hypertension | Selectivity Assay (Need Lentivirus for ADRA1A/1B/1D stable cells) |
| Peptide / Biologic | Emerging Biotechs | Neurological / PTSD | Signaling Pathway Validation (Need Sequence Verified ORFs) |
| Combination Therapy | GSK, Eli Lilly, Various Phase II | Refractory Urological Conditions, BPH + Erectile Dysfunction | Phenotypic Screening (Need Benchmark Abs for receptor tracking) |
Key Genetic Variations
ADRA1A carries notable somatic and germline mutations relevant to drug response and disease association:
- Somatic mutation in a breast cancer sample (UniProt P35348 VAR_035756) – may influence tumor microenvironment signaling.
- dbSNP:rs2229125 (UniProt P35348 VAR_049370) – potential functional variant.
- dbSNP:rs1048101 (UniProt P35348 VAR_019509) – associated with differential receptor expression or activity.